The Expanding Role of JAK Inhibitors in MF
The Expanding Role of JAK Inhibitors in MF CME, CPE Ruben Mesa, MD | ||
Release Date: June 16, 2021 Expiration Date: June 16, 2022 | ||
Join Dr. Mesa as he discusses new opportunities for JAK inhibitors in myelofibrosis (MF). Topics will include the ruxolitinib phase 3 COMFORT I and II trials, management of early-onset treatment-associated cytopenia, and outcomes associated with fedratinib in the JAKARTA and JAKARTA-2 trials Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation. | ||
View Only, No Credit | ||